NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis.
Adalimumab
/ pharmacology
Adaptor Proteins, Signal Transducing
/ genetics
Adolescent
Adult
Aged
Alleles
Alternative Splicing
Female
Gene Frequency
Genetic Predisposition to Disease
Genotype
HLA-C Antigens
/ genetics
Humans
INDEL Mutation
Male
Middle Aged
Polymorphism, Single Nucleotide
Psoriasis
/ drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Young Adult
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
4
7
2019
medline:
8
5
2020
entrez:
4
7
2019
Statut:
ppublish
Résumé
Nuclear factor (NF)-κB is an essential mediator of the tumor necrosis factor (TNF) pathway, and has been implicated in psoriasis. NFKBIZ is a nuclear inhibitor of NF-κB with a prominent role in the pathogenesis of psoriasis. The genetic variation at the NFKBIZ gene has been associated with the risk of developing psoriasis, and could also contribute to defining the response to anti-TNF biological drugs. The objectives of this study were to determine the association of a common NFKBIZ insertion/deletion (indel) polymorphism (rs3217713) with the response to adalimumab and determine the differences in the relative expression of a NFKBIZ alternative transcript in patients with a positive versus negative response. We genotyped a common NFKBIZ polymorphism in 169 psoriasis patients treated with adalimumab classified as responders (n = 120) and non-responders (n = 49), according to whether they had a 75% reduction in the Psoriasis Area and Severity Index score (PASI75) at week 24. The Cw6 polymorphism was also determined and allele and genotype frequencies were compared between the groups. We also determined the rate of the expression of a NFKBIZ transcript lacking exon 10 relative to the normal transcript in 60 patients (27 non-responders). In addition, because the intron indel could affect RNA splicing, we investigated whether the level of the alternative transcript was related to the intronic genotype. The NFKBIZ polymorphism was associated with adalimumab response, with carriers of the deletion allele significantly more frequent among responders (odds ratio = 2.76, 95% confidence interval 1.19-6.43; p = 0.015). The presence of the HLA-CW6 allele was also associated with a positive response in our cohort (p = 0.018). The alternative transcript was amplified in all the samples. We found higher but non-significant values of normal to alternative transcript in responders as well as in NFKBIZ insertion homozygotes. Our study supported a significant effect of a common NFKBIZ polymorphism on the response to adalimumab. This result could help to optimize the prescription of this anti-TNF, but requires confirmation in other cohorts.
Sections du résumé
BACKGROUND
Nuclear factor (NF)-κB is an essential mediator of the tumor necrosis factor (TNF) pathway, and has been implicated in psoriasis. NFKBIZ is a nuclear inhibitor of NF-κB with a prominent role in the pathogenesis of psoriasis. The genetic variation at the NFKBIZ gene has been associated with the risk of developing psoriasis, and could also contribute to defining the response to anti-TNF biological drugs.
OBJECTIVES
The objectives of this study were to determine the association of a common NFKBIZ insertion/deletion (indel) polymorphism (rs3217713) with the response to adalimumab and determine the differences in the relative expression of a NFKBIZ alternative transcript in patients with a positive versus negative response.
METHODS
We genotyped a common NFKBIZ polymorphism in 169 psoriasis patients treated with adalimumab classified as responders (n = 120) and non-responders (n = 49), according to whether they had a 75% reduction in the Psoriasis Area and Severity Index score (PASI75) at week 24. The Cw6 polymorphism was also determined and allele and genotype frequencies were compared between the groups. We also determined the rate of the expression of a NFKBIZ transcript lacking exon 10 relative to the normal transcript in 60 patients (27 non-responders). In addition, because the intron indel could affect RNA splicing, we investigated whether the level of the alternative transcript was related to the intronic genotype.
RESULTS
The NFKBIZ polymorphism was associated with adalimumab response, with carriers of the deletion allele significantly more frequent among responders (odds ratio = 2.76, 95% confidence interval 1.19-6.43; p = 0.015). The presence of the HLA-CW6 allele was also associated with a positive response in our cohort (p = 0.018). The alternative transcript was amplified in all the samples. We found higher but non-significant values of normal to alternative transcript in responders as well as in NFKBIZ insertion homozygotes.
CONCLUSION
Our study supported a significant effect of a common NFKBIZ polymorphism on the response to adalimumab. This result could help to optimize the prescription of this anti-TNF, but requires confirmation in other cohorts.
Identifiants
pubmed: 31267486
doi: 10.1007/s40291-019-00409-x
pii: 10.1007/s40291-019-00409-x
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
HLA-C Antigens
0
HLA-C*06 antigen
0
NFKBIZ protein, human
0
Tumor Necrosis Factor-alpha
0
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-633Références
Expert Opin Biol Ther. 2019 Jan;19(1):45-54
pubmed: 30500317
Exp Dermatol. 2017 Mar;26(3):234-241
pubmed: 27576147
Mol Diagn Ther. 2017 Jun;21(3):295-301
pubmed: 28130758
Pharmacogenomics J. 2014 Dec;14(6):526-34
pubmed: 24776844
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5825-33
pubmed: 26460049
J Invest Dermatol. 2016 Aug;136(8):1608-1616
pubmed: 27117051
Immunity. 2007 Aug;27(2):296-307
pubmed: 17692539
Pharmacogenomics J. 2018 Jan;18(1):76-80
pubmed: 27670766
Dermatology. 2016;232(2):230-6
pubmed: 26678060
Expert Opin Drug Saf. 2017 Oct;16(10):1173-1179
pubmed: 28750567
J Biol Chem. 2011 Jul 22;286(29):25487-94
pubmed: 21628458
Pharmacogenet Genomics. 2015 Jun;25(6):313-6
pubmed: 25794162
Pharmacogenomics. 2017 Jul;18(10):945-953
pubmed: 28639493
Oncogene. 2006 Oct 30;25(51):6758-80
pubmed: 17072327
Pharmacogenet Genomics. 2016 Sep;26(9):423-7
pubmed: 27348478
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1786-90
pubmed: 25726968
Nature. 2004 Jul 8;430(6996):218-22
pubmed: 15241416
Cell Signal. 2003 Jan;15(1):1-7
pubmed: 12401514
Nature. 2010 Apr 29;464(7293):1381-5
pubmed: 20383124
BioDrugs. 2014 Dec;28(6):487-97
pubmed: 24890029
Hum Immunol. 2017 May - Jun;78(5-6):435-440
pubmed: 28259733
Nat Commun. 2014 Jul 09;5:4331
pubmed: 25006012
Exp Dermatol. 2018 Sep;27(9):1048-1052
pubmed: 29938836
BioDrugs. 2013 Oct;27(5):439-52
pubmed: 23620106
Recent Pat Inflamm Allergy Drug Discov. 2009 Jan;3(1):40-8
pubmed: 19149745
Nat Commun. 2015 May 05;6:7001
pubmed: 25939698
J Am Acad Dermatol. 2016 Feb;74(2):374-5
pubmed: 26775778
Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72
pubmed: 25169849
Pharmacogenomics. 2018 Jan;19(1):7-16
pubmed: 29192552
J Invest Dermatol. 2005 Jun;124(6):1275-83
pubmed: 15955104
J Dermatol Sci. 2013 Feb;69(2):89-94
pubmed: 23219896
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Ann Rheum Dis. 2010 Jul;69(7):1315-20
pubmed: 20448286